What the FDA labels say about taking them together
Digoxin and sofosbuvir/velpatasvir/voxilaprevir
Sofosbuvir/velpatasvir/voxilaprevir's FDA label of July 14, 2025 names digoxin in its drug interactions section; the digoxin labels PlainMeds reads (3) do not name sofosbuvir/velpatasvir/voxilaprevir. The sofosbuvir/velpatasvir/voxilaprevir label: “Therapeutic concentration monitoring of digoxin is recommended when coadministered with VOSEVI. Refer to digoxin prescribing information for monitoring and dose modification recommendations for concentration increases …”
Check it at the source: the digoxin FDA label on DailyMed (effective December 5, 2024, Advanz Pharma (US) Corp.); the sofosbuvir/velpatasvir/voxilaprevir FDA label on DailyMed (effective July 14, 2025, Gilead Sciences, Inc.).
What does the digoxin label say about sofosbuvir/velpatasvir/voxilaprevir?
Digoxin's label (effective December 5, 2024) and its 2 other brand-application labels do not name sofosbuvir/velpatasvir/voxilaprevir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (LANOXIN), Advanz Pharma (US) Corp., effective December 5, 2024 (SPL set d91e3646-4c63-4512-ab22-db39c085c4dc), via openFDA; the full label on DailyMed
What does the sofosbuvir/velpatasvir/voxilaprevir label say about digoxin?
Sofosbuvir/velpatasvir/voxilaprevir label, drug interactionsConcomitant Drug Class/Drug Name: digoxin; Effect on Concentration ↓ = decrease, ↑ = increase.: ↑ digoxin; Clinical Effect/Recommendation: Therapeutic concentration monitoring of digoxin is recommended when coadministered with VOSEVI. Refer to digoxin prescribing information for monitoring and dose modification recommendations for concentration increases with unclear magnitude.
Source: FDA drug label (Vosevi), Gilead Sciences, Inc., effective July 14, 2025 (SPL set 17ffc094-8ca7-45d2-80d8-fd043bc9a221), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Digoxin | Sofosbuvir/velpatasvir/voxilaprevir | |
|---|---|---|
| Labeled for | Heart failure, Atrial fibrillation | Hepatitis C |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.133 per tablet 125 mcg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once